Phase 2 Vitiligo Trial: Microneedling, Minoxidil 5%, NB-UVB Phototherapy
Summary
ClinicalTrials.gov registered a Phase 2 randomized controlled trial (NCT07548918) evaluating microneedling with topical minoxidil 5% alone versus microneedling with minoxidil combined with NB-UVB phototherapy in 30 patients with non-segmental stable vitiligo. The study aims to assess both clinical and histopathological outcomes, including immunohistochemical changes in Wnt/β-catenin signaling expression in lesional skin. The combination therapy is designed to enhance repigmentation by improving melanocyte activation, drug delivery, and angiogenesis.
“This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A Phase 2 randomized controlled trial (NCT07548918) has been registered on ClinicalTrials.gov under NIH, comparing two treatment approaches for stable vitiligo: microneedling with topical minoxidil 5% alone versus microneedling with minoxidil combined with NB-UVB phototherapy. The trial will enroll 30 patients with non-segmental stable vitiligo and evaluate both clinical outcomes and histopathological changes, particularly Wnt/β-catenin signaling expression in lesional skin. The study is classified as Phase 2 with an anticipated start date of April 23, 2026.
Healthcare providers and clinical investigators involved in dermatology or vitiligo research should be aware of this trial's design, which may inform future combination therapy approaches. Sponsors and pharmaceutical companies developing minoxidil formulations or phototherapy devices may find this trial relevant to their product development strategies. The trial represents an addition to the clinical research landscape for depigmentation disorders and does not create immediate compliance obligations for the industry.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo"
Phase 2 NCT07548918 Kind: PHASE2 Apr 23, 2026
Abstract
This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo.
It aims to evaluate both clinical and histopathological outcomes in 30 patients with non-segmental stable vitiligo.
Vitiligo is a chronic depigmenting disorder caused by melanocyte destruction with significant psychosocial impact.
The study also investigates immunohistochemical changes, particularly Wnt/β-catenin signaling expression in lesional skin.
The combination therapy is expected to enhance repigmentation by improving melanocyte activation, drug delivery, and angiogenesis
Conditions: Vitiligo - Macular Depigmentation
Interventions: microneedling with minoxidil 5% and NBUVB, Microneedling with Minoxidil5%
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.